Advertisement

Advertisement
COVID-19
Immunotherapy

Short-Term Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients Receiving Immunotherapy

In an Israeli case-control study reported in a commentary in The Lancet Oncology, Waissengrin et al found that the short-term safety of the...

Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Directions

Although head and neck cancers include multiple histologies and primary sites, squamous cell carcinoma (SCC) originating in the oropharynx...

Breast Cancer

Addition of Alpelisib to Fulvestrant for PIK3CA-Mutant, HR-Positive, HER2-Negative Advanced Breast Cancer: Patient-Reported Outcomes

In an analysis from the PIK3CA-mutant cohort of the phase III SOLAR-1 trial reported in the Journal of Clinical OncologyEva Ciruelos, MD, PhD, and colleagues...


Advertisement
Lymphoma
Immunotherapy

Integration of Brentuximab Vedotin Into Front-Line Treatment for Pediatric Patients With High-Risk Hodgkin Lymphoma

In a study reported in the Journal of Clinical Oncology, Metzger et al found that the integration of brentuximab vedotin into front-line treatment...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Gynecologic Cancers
Immunotherapy

Emily Hinchcliff, MD, MPH, on Treating Non–Clear Cell Ovarian Cancer With Durvalumab and Tremelimumab

Head and Neck Cancer
Genomics/Genetics

Tipifarnib for Patients With Advanced HRAS-Mutant Head and Neck Cancer and High Variant Allele Frequency

In a phase II trial reported in the Journal of Clinical Oncology, Ho et al found that tipifarnib produced a high response rate among patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations and high variant allele frequency. As stated by the investigators,...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Gynecologic Cancers
Immunotherapy

Hyun C. Chung, MD, on Pembrolizumab for Advanced Cervical Cancer: Update From KEYNOTE-158

Hepatobiliary Cancer

Second-Line FOLFOX vs Active Symptom Control in Advanced Biliary Tract Cancer

In the phase III ABC-06 trial reported in The Lancet Oncology, Angela Lamarca, PhD, and colleagues found that second-line FOLFOX (leucovorin, fluorouracil [5-FU], and oxaliplatin) produced a statistically significant improvement in median overall survival vs active symptom control in patients with...

Patrizia Cavazzoni, MD, Named Director of the FDA’s Center for Drug Evaluation and Research

On April 12, Patrizia Cavazzoni, MD, was announced as the Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA).  Janet Woodcock, MD, Acting Commissioner of the FDA, noted on Twitter: “Pleased to announce the permanent appointment of Patrizia ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Lymphoma

Matthew J. Matasar, MD, on Indolent NHL: New Data on Copanlisib Plus Rituximab

Skin Cancer

Unselected Autologous Tumor-Infiltrating Lymphocyte Therapy for Metastatic Cutaneous Melanoma

Treatment with unselected autologous tumor-infiltrating lymphocytes (TILs) showed early clinical efficacy among patients with advanced melanoma, according to results presented by Hawkins et al during week 1 of the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 (Abstract ...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...